{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001897","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.169896+00:00","generated_at":"2026-06-19T01:55:01.258902+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium Q4 record net revenue $129.6M; FY22 adj. EBITDA $266.0M, reaffirms 2023 guidance","bullets":["Q4 product revenue $129.6M (up from $27.4M YoY); GAAP net loss $(7.2)M vs $(25.0)M YoY.","FY22 product revenue $463.9M (up 68% YoY); non-GAAP adjusted EPS $3.96 vs $2.58.","Completed BDSI integration with $85M run-rate synergies; resolved all 27 opioid lawsuits.","Board authorized $100M share repurchase program in Jan 2023; cash balance $173.7M at year-end.","Reaffirms 2023 guidance: product revenue $565-580M, adjusted EBITDA $355-370M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001897","json":"https://secwatch.observer/filing/0001558370-23-001897.json","markdown":"https://secwatch.observer/filing/0001558370-23-001897.md","text":"https://secwatch.observer/filing/0001558370-23-001897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/coll-20230223x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:55:01.258902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"878c32a3bec10ce9641c6445eb62b27800c8b2bd","claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended December 31, 2022 results: revenue $129.6 million, net income $(7.2) million, EPS $(0.21) GAAP loss per share (basic and diluted). Guidance reaffirmed.","evidence_excerpt":"● Product revenues, net were $129.6 million for the quarter ended December 31, 2022 (the “2022 Quarter”), compared to $27.4 million for the quarter ended December 31, 2021 (the “2021 Quarter”). ● GAAP operating expenses were $38.0 million for the 2022 Quarter, compared to $32.8 million for the 2021 Quarter. Adjusted operating expenses, which exclude stock-based compensation expense of $5.7 million and acquisition related expenses of $0.1 million, were $32.3 million for the 2022 Quarter, compared to $20.4 million for the 2021 Quarter, which excluded stock-based compensation expense of $4.9 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for the 2022 Quarter was $(7.2) million, with $(0.21) GAAP loss per share (basic and diluted), compared to GAAP net loss for the 2021 Quarter of $(25.0) million, with $(0.73) GAAP loss per share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$129.6 million"},{"label":"Net income","value":"$(7.2) million"},{"label":"EPS","value":"$(0.21) GAAP loss per share (basic and diluted)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a9dcfa27268f46e6ed210d66ab26fb83d5883d57","claim":"COLLEGIUM PHARMACEUTICAL, INC reported the year ended December 31, 2022 results: revenue $463.9 million, net income $(25.0) million, EPS $(0.74) GAAP loss per share (basic and diluted). Guidance reaffirmed.","evidence_excerpt":"● Product revenues, net were $463.9 million for the year ended December 31, 2022 (“FY 2022”), compared to $276.9 million for the year ended December 31, 2021 (“FY 2021”). ● GAAP operating expenses were $176.2 million for FY 2022, compared to $133.0 million for FY 2021. Adjusted operating expenses, which exclude stock-based compensation of $22.9 million and acquisition related expenses of $31.3 million, were $122.0 million for FY 2022, compared to $101.2 million for FY 2021, which excluded stock-based compensation expense of $24.3 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for FY 2022 was $(25.0) million, with $(0.74) GAAP loss per share (basic and diluted), compared to GAAP net income for FY 2021 of $71.5 million, with $2.05 GAAP earnings per share (basic) and $1.86 GAAP earnings per share (diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$463.9 million"},{"label":"Net income","value":"$(25.0) million"},{"label":"EPS","value":"$(0.74) GAAP loss per share (basic and diluted)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}